- Home
- MYN vs LXEO Comparison
MYN vs LXEO Comparison
Compare MYN & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MYN | LXEO |
|---|---|---|
| Founded | 1992 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.1M | 369.8M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | MYN | LXEO |
|---|---|---|
| Price | $9.99 | $4.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | 125.9K | ★ 731.1K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.13 | $3.60 |
| 52 Week High | $10.26 | $10.99 |
Technical Indicators
Market Signals| Indicator | MYN | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 35.19 |
| Support Level | $9.87 | N/A |
| Resistance Level | $10.19 | $7.90 |
| Average True Range (ATR) | 0.09 | 0.33 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 80.85 | 2.84 |
Price Performance
Historical ComparisonAbout MYN Blackrock MuniYield New York Quality Fund Inc.
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.